The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment
in patients with type 2 diabetes results in improved sleep duration and quality and to
explore the relationship between improvements in sleep and measures of metabolic and
circadian function. This project would be the first to probe the relationship between
incretin hormone regulation, duration and intensity of sleep, glucose tolerance and circadian
dysfunction in diabetic patients.